Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer.
24 November 2022
21 November 2022
08 November 2022
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies
Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022
IMC Half Year Results, Feb 2022
IMC Full Year Results, Oct 2021
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
